Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?
John S. Macdonald MD FACP
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles about his data on the relevance of KRAS tumor status to the choice of molecular therapy for patients with metastatic colorectal cancer. Whether the gene is wild-type or mutant determines sensitivity of the tumor to anti-epidermal growth factor or anti-vascular endothelial growth factor receptor therapy. Dr Macdonald also discusses the disappointing finding that blocking both of these proliferation pathways does not lead to improved efficacy when two targeted drugs are used in combination.
LISTEN
[audio:https://www.audiomedica.com/podcasting/otbn/090426JohnMacdonaldOTBN.mp3]
